This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

BCG immunotherapy in bladder tumours

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Intravesical BCG has been used to treat bladder cancer since the late 1970's. Given once a week for 6-12 weeks, it destroys carcinoma in situ and superficial tumours, and causes measurable changes in the immune system.

The main problem with intravesical BCG is it's side-effects:

  • systemic "BCG-osis" with lung granulomas, disturbed liver function, fever and malaise; requires prompt anti-tuberculous chemotherapy as may be fatal
  • chemical cystitis
  • flu-like symptoms

Consequently, BCG is usually reserved for:

  • carcinoma in situ
  • high grade superficial tumours i.e. pT1G3
  • pTa and pT1 tumours that have failed to respond to other treatments

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page